Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy

- Jerusalem, G., Farah, S., Abdi, E., Kamby, C., Thompson, A., Loibl, S., Gavilá, J., Kuroi, K., Marth, C., Müller, B., O'Reilly, S., Gombos, A., Courtois, A., Ruhstaller, T., Burstein, HJ, Rabaglio, M., Ruepp, B, Ribi, K, Viale, G, Gelber, RD, Coates, AS, Loi, S, Goldhirsch, A, Chirgwin, J., Regan, MM, Colleoni, M, Aebi, S., Karlsson, P., Neven, P., Hitre, E., Graas, M. P., Simoncini, E.

Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem)

- McCarthy, N., Boyle, F., Gebski, V., Veillard, A. S., Zannino, D., Wilcken, N., Reaby, L., Lindsay, D. F., Badger, H. D., Forbes, J. F., Zdenkowski, N., Bull, J., Leong, E., Simpson, A., Kannourakis, G., Francis, P. A., Chirgwin, J., Abdi, E.

Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy

- Hovey, E., Lloyd, A., Abdi, E., de Souza , P., Marx, G., Parente, P., Rapke, T., Hill, A., Bonaventura, A., Michele, A., Craft, P.